Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 22, 2026

MSD’s Keytruda and Padcev combination receives EC approval

The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults.

The EC assessment was based on the Phase III KEYNOTE-B15 study, conducted alongside Astellas and Pfizer. Credit: PeopleImages / Shutterstock.com.